Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 10/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9225175 | 0.85 | LMNA (0.67) | LMNATDP1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL14576206 | 0.79 | KMT2A (0.62) | LMNATDP1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL30468041 | 0.78 | MAPT (0.70) | LMNATDP1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1700307 | 0.78 | MAPT (0.70) | LMNATDP1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17841231 | 0.77 | LMNA (0.76) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL29483590 | 0.77 | LMNA (0.76) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL29483577 | 0.77 | LMNA (0.76) | LMNAMAPTMAPK1ALDH1A1GAA | |
| SCHEMBL3994858 | 0.76 | LMNA (0.65) | LMNAMAPTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL2716434 | 0.75 | LMNA (0.70) | LMNATDP1MAPTL3MBTL1MAPK1 | |
| SCHEMBL2546137 | 0.75 | MAPT (0.64) | LMNAMAPTSMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552208-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | LMNA 2804/4885TDP1 1322/4885MAPT 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.